Abeona Therapeutics Price Target Maintained With a $18.00/Share by Cantor Fitzgerald
Stifel Maintains Abeona Therapeutics(ABEO.US) With Buy Rating, Maintains Target Price $21
Analysts Conflicted on These Healthcare Names: Abeona Therapeutics (ABEO), Cyclacel Pharmaceuticals (CYCC) and Cardinal Health (CAH)
Abeona Therapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $15 Price Target
H.C. Wainwright Maintains Abeona Therapeutics(ABEO.US) With Buy Rating, Maintains Target Price $15
Buy Rating on Abeona Therapeutics Bolstered by Positive Medicare Decisions and FDA Approval Progress
Stifel Maintains Abeona Therapeutics(ABEO.US) With Buy Rating, Maintains Target Price $21
Abeona Therapeutics Analyst Ratings
Stifel Nicolaus Sticks to Its Buy Rating for Abeona Therapeutics (ABEO)
Abeona Therapeutics Analyst Ratings
Abeona Therapeutics Analyst Ratings
Abeona Therapeutics Inc.: Stifel starts insurance with a purchase rating; target price is $21
Abeona Therapeutics Analyst Ratings
Cantor Fitzgerald Maintains Overweight on Abeona Therapeutics, Lowers Price Target to $21
Cantor Fitzgerald Inc.: The Abeona Therapeutics (ABEO.US) rating was reaffirmed and adjusted from an increase in holdings to an increase rating, with a target price of $36.00.
Abeona Therapeutics Analyst Ratings
Abeona Therapeutics Analyst Ratings
Abeona Therapeutics Analyst Ratings
Alliance Global Partners Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target